FDA 483 - Evonik Corporation - December 10, 2024

Evonik Corporation in Birmingham, AL, a drug manufacturer, was cited for significant deficiencies in cleanroom controls, environmental monitoring, facility maintenance, equipment calibration, and quality unit procedures during an FDA inspection. The observations indicate a lack of adequate controls to prevent contamination and ensure proper drug product manufacturing. These issues suggest a moderate level of severity regarding GMP compliance.